PT  - JOURNAL ARTICLE
AU  - Nobuyuki Oyama
AU  - Hironobu Akino
AU  - Hiroshi Kanamaru
AU  - Yuji Suzuki
AU  - Satoshi Muramoto
AU  - Yoshiharu Yonekura
AU  - Norihiro Sadato
AU  - Kazutaka Yamamoto
AU  - Kenichiro Okada
TI  - <sup>11</sup>C-Acetate PET Imaging of Prostate Cancer
DP  - 2002 Feb 01
TA  - Journal of Nuclear Medicine
PG  - 181--186
VI  - 43
IP  - 2
4099  - http://jnm.snmjournals.org/content/43/2/181.short
4100  - http://jnm.snmjournals.org/content/43/2/181.full
SO  - J Nucl Med2002 Feb 01; 43
AB  - 11C-Acetate can act as a probe of tissue metabolism through entry into catabolic or anabolic metabolic pathways as mediated by acetyl–coenzyme A. The uptake of 11C-acetate in prostate cancer was investigated to determine whether this tracer has potential in tumor identification. Methods: Twenty-two patients with prostate cancer underwent PET after intravenous administration of 740 MBq 11C-acetate. Eighteen of the 22 patients were also investigated with 18F-FDG PET. Standardized uptake values (SUVs) for each tumor were investigated for tracer activity at 10–20 min after 11C-acetate and 40–60 min after 18F-FDG administration. Results: Adenocarcinoma of the prostate showed variable uptake of 11C-acetate, with SUVs ranging from 3.27 to 9.87. In contrast, SUVs for 18F-FDG ranged from 1.97 to 6.34. By visual inspection, 11C-acetate accumulation in primary prostate tumors was positive in all patients, whereas 18F-FDG accumulation was positive in only 15 of 18 patients. 11C-Acetate PET in a patient with lymph node metastasis showed high intrapelvic accumulation corresponding to metastatic sites. Similarly, 2 patients with bone metastases were 11C-acetate avid. Conclusion: 11C-Acetate shows marked uptake in prostate cancer and is more sensitive in detection of prostate cancer than is 18F-FDG PET. 11C-Acetate represents a new tracer for detection of prostate cancer with PET, measuring radiopharmaceutical uptake pathways that are different from those measured by 18F-FDG.